1 Bulgaria Country Drug Report 2017 THE DRUG PROBLEM IN BULGARIA AT A GLANCE Drug use High-risk opioid users Treatment entrants Overdose deaths HIV diagnoses attributed to injecting Drug law offences in young adults (15-34 years) in the last year by primary drug 8.3 % 4 195 Top 5 drugs seized Population No data Opioid substitution treatment clients 3 423 through specialised programmes ranked according to quantities measured in kilograms 1. Herbal cannabis 2. Heroin 3. Amphetamine 4. Methamphetamine 5. Cannabis resin Syringes distributed 364 111 4 763 637 Other drugs Cannabis MDMA 2.9 % Amphetamines 1.3 % Cocaine 0.3 % Cannabis, 3 % Amphetamines, 5 % Cocaine, 2 % Heroin, 73 % Other, 17 % 0 10 20 30 40 50 60 70 80 26 0 10 20 30 40 50 60 70 80 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 17 11.6 % 4.8 % Syringes distributed (15-64 years) Source: EUROSTAT Extracted on: 26/03/2017 Source: ECDC Contents: At a glance | National drug strategy and coordination (p. 2) | Public expenditure (p. 2) | Drug laws and drug law offences (p. 3) | Drug use (p. 4) | Drug harms (p. 7) | Prevention (p. 9) | Harm reduction (p. 10) | Treatment (p. 11) | Drug use and responses in prison (p. 13) | Quality assurance (p. 14) | Drug-related research (p. 14) | Drug markets (p. 15) | Key drug statistics for Bulgaria (p. 17) | EU Dashboard (p. 19) NB: Data presented here are either national estimates (prevalence of use, opioid drug users) or reported numbers through the EMCDDA indicators (treatment clients, syringes, deaths and HIV diagnosis, drug law offences and seizures). Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.
20
Embed
Bulgaria - Country Drug Report 2017 · 1 Bulgaria Country Drug Report 2017 THE DRUG PROBLEM IN BULGARIA AT A GLANCE Drug Treatment entrantsuse High-risk opioid users Overdose deaths
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
BulgariaCountry Drug Report 2017
THE DRUG PROBLEM IN BULGARIA AT A GLANCE
Drug use
High-risk opioid users
Treatment entrants Overdose deaths
HIV diagnoses attributed to injecting
Drug law o�ences
in young adults (15-34 years) in the last year
by primary drug
8.3 %4 195
Top 5 drugs seized
Population
No data
Opioid substitution treatment clients
3 423
through specialised programmes
ranked according to quantitiesmeasured in kilograms
Source: EUROSTATExtracted on: 26/03/2017Source: ECDC
Contents: At a glance | National drug strategy and coordination (p. 2) | Public expenditure (p. 2) | Drug laws
and drug law offences (p. 3) | Drug use (p. 4) | Drug harms (p. 7) | Prevention (p. 9) | Harm reduction (p. 10) |
Treatment (p. 11) | Drug use and responses in prison (p. 13) | Quality assurance (p. 14) | Drug-related research
(p. 14) | Drug markets (p. 15) | Key drug statistics for Bulgaria (p. 17) | EU Dashboard (p. 19)
NB: Data presented here are either national estimates (prevalence of use, opioid drug users) or reported numbers through the EMCDDA indicators (treatment clients, syringes, deaths and HIV diagnosis, drug law offences and seizures). Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.
Country Drug Report 2017 — Bulgaria
2
National drug strategy and coordination
National drug strategy
Adopted by the Council of Ministers in 2014, Bulgaria’s
National Anti-Drug Strategy (2014-18), with its associated
action plan and financial plan, addresses issues related
to illicit drugs (Figure 1). The strategy is built around the
pillars of drug demand and drug supply reduction and has
three joint activity areas. Its main demand reduction goals
are to improve public health and the health and social
functioning of individuals; to protect society from drug
markets; and to reduce the demand for illicit drugs. In
the area of supply reduction, the goals are to reduce the
supply of illicit drugs and their precursors; to increase the
efficiency of law enforcement and supervisory authorities;
to enhance prevention of drug-related crimes; and to
ensure effective cooperation using a joint and coordinated
approach. In Bulgaria, drug policy and the National Anti-
Drug Strategy (2014-18) are evaluated through ongoing
indicator monitoring and specific research projects.
National coordination mechanisms
The National Drugs Council is a body of the Council of
Ministers of the Republic of Bulgaria. Operating at the inter-
ministerial level, it is responsible for the implementation
and coordination of illicit drug policy. It is chaired by the
Minister of Health and includes representatives from all
relevant ministries. The Narcotic Substances Section is
part of the Pharmaceutical Products, Medical Devices and
Narcotic Substances Directorate of the Ministry of Health. It
is responsible for assisting the Minister of Health to control
scheduled substances for medical purposes and meet
Bulgaria’s obligations under international drug control
treaties. The National Centre of Addictions houses the
national focal point for the EMCDDA and is responsible for
the collection and analysis of a range of drug-related data.
Local level coordination is undertaken by 27 municipal
councils on narcotic substances and 27 prevention and
information centres.
Public expenditure
Understanding the costs of drug-related actions is an
important aspect of drug policy.
In past years, the financing of drug-related activities in
Bulgaria was decided annually by the entities that were
in charge of their implementation. However, the two last
national drug strategies (for 2009-13 and for 2014-18)
have been important guides for the planning of public
financing for drug-related initiatives. Preliminary estimates
indicate that, in 2015, a total of approximately BGN 2
million (approximately EUR 1 million) was allocated for
labelled drug-related expenditure, which represented about
0.01 % of gross domestic product (GDP).
FIGURE 1Focus of national drug strategy documents: illicit drugs or broader
Illicit drugs focus
Broader focus
BulgariaIllicit drugs focus
NB: Year of data 2015. Strategies with broader focus may include, for example, licit drugs and other addictions.
About this report
This report presents the top-level overview of the drug
phenomenon in Bulgaria, covering drug supply, use
and public health problems as well as drug policy and
responses. The statistical data reported relate to 2015 (or
most recent year) and are provided to the EMCDDA by the
national focal point, unless stated otherwise.
An interactive version of this publication, containing links to
online content, is available in PDF, EPUB and HTML format:
Clients in substitution treatment 2015 3 423 252 168 840
Treatment demand
All clients 2015 2 131 282 124 234
First-time clients 2015 560 24 40 390
Drug law offences
Number of reports of offences 2015 4 195 472 411 157
Offences for use/possession No data No data 359 390 843
* PWID — people who inject drugs.
Country Drug Report 2017 — Bulgaria
19
EU Dashboard
0.4 %
10
15
20
25
CZFR IT DK ES NL EE FI UKDEHR IE SI BE PL NO BGSKLVAT SE HULT PT CY RO ELTR LU MT
4 %22.1 %
0.2 %0.3 %
UK ESNL IE FRDK NO IT DEEE SI ATFIHR BECY CZPLHU PT SKBGLV LT RO EL SE TRLU MT
6.6 %
0.1 %NL CZ UK BG FI FREE ES ITATHU SKIE DE PL CYSI BELV DK PTHR NO ELLT RO SETR LU MT
3.1 %
0.1 %
1.3 %
NL EE FI CZ DEHR DK BG ESHU UK NOAT IESI FR ITLV BELT PL CYSK PT ELRO TR SELU MT
3.6cases/million
HIV infections
8.1
0.3UK LUMT FRITAT PT LV FI SI HR DE NO EL LTESCY CZ SKNL PL HU TR EEDKBG IEBE RO SE
44.3
0RO ITUK ES DEEL FRBGPTLT PLIE ATLU DK BE CZ TRSE FINO CY SISK HU MTHR NL
HCV antibody prevalence
EE SE NO IE UK LT DK FI LU MT AT DE SI HR NL CY ES LV TR PL BE IT SK FR PT CZ HU BG ROEL
102.7
1.63.6
PT ES EL NO IT DK HU LV CY SI IE TR MT AT CZ BE BG HR EE FI FR DE LT LU NL PL RO SK SE UK
15.7 %
83.5 %
CannabisLast year prevalence among young adults (15-34 years)
CocaineLast year prevalence among young adults (15-34 years)
Last year prevalence among young adults (15-34 years)MDMA
Opioids
Last year prevalence among young adults (15-34 years)Amphetamines
National estimates among adults (15-64 years)High-risk opioid use (rate/1 000)
National estimates among injecting drug usersNewly diagnosed cases attributedto injecting drug use
Drug-induced mortality rates
LV EE
No data
3.6
0
0
8.3 % 0.3 %
2.9 % 1.3 %
3.6cases/million
No data
8.3 %
2.9 %
NB: Caution is required in interpreting data when countries are compared using any single measure, as, for example, differences may be due to reporting practices. Detailed information on methodology, qualifications on analysis and comments on the limitations of the information available can be found in the EMCDDA Statistical Bulletin. Countries with no data available are marked in white.
Country Drug Report 2017 — Bulgaria
20
About the EMCDDA
About our partner in BulgariaThe national focal point (NFP) is based in the National Centre for
Addictions. The unit carries out informational, analytical, scientific
research, expert-consultative and publishing activities. The main
objectives of NFP activities include methodological control,
collection, evaluation and classification, processing, storage, analysis
and dissemination of information in the field of drug demand and
supply in Bulgaria, drug policy and the response to the situation in
that field. The NFP works on the provision of information, supporting
the activity of the National Drug Council and the formulation of a
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the central source and confirmed authority on drug-related issues in Europe. For over 20 years, it has been collecting, analysing and disseminating scientifically sound information on drugs and drug addiction and their consequences, providing its audiences with an evidence-based picture of the drug phenomenon at European level.
The EMCDDA’s publications are a prime source of information for a wide range of audiences including: policymakers and their advisors; professionals and researchers working in the drugs field; and, more broadly, the media and general public. Based in Lisbon, the EMCDDA is one of the decentralised agencies of the European Union.
Recommended citation
European Monitoring Centre for Drugs and Drug Addiction (2017), Bulgaria, Country Drug Report 2017, Publications Office of the European Union, Luxembourg.
TD-04-16-909-EN-N
Legal notice: The contents of this publication do not necessarily reflect the official opinions of the EMCDDA’s partners, the EU
Member States or any institution or agency of the European Union. More information on the European Union is available on the
Internet (europa.eu).
Luxembourg: Publications Office of the European Union